IP Library Granted Patent US 8,846,095
Granted Patent B2
US 8,846,095 · App. 12/742,439 · Granted Sep 30, 2014

Dextran-based polymer tissue adhesive for medical use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,095
App. No.
12/742,439
Granted
Sep 30, 2014
Kind
B2
Abstract

A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.

Claims (25)

1. A kit comprising:

a) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; and

b) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons; wherein the at least one aminodextran and the at least one oxidized dextran are unreacted.

2. The kit according to claim 1 wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran a second aqueous solution or dispersion.

3. The kit according to claim 2 wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to the total weight of the solution or dispersion.

4. The kit according to claim 2 wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.

5. The kit according to claim 1 wherein the aminodextran and the oxidized dextran are finely divided powders.

6. The kit according to claim 1 wherein the equivalent weight per aldehyde group of the oxidized dextran is about 90 to about 1500 Daltons.

7. A dried hydrogel product formed by a process comprising the steps of:

a) reacting in a solvent (i) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; with (ii) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons, to form a hydrogel;

b) treating said hydrogel to remove at least a portion of said solvent to form the dried hydrogel.

8. The dried hydrogel according to claim 7 , wherein said dried hydrogel is a film.

9. The dried hydrogel according to claim 7 wherein the process further comprises comminuting the dried hydrogel to form finely divided particles.

10. The dried hydrogel according to claim 7 , wherein the equivalent weight per aldehyde group of the oxidized dextran is about 90 to about 1500 Daltons.

11. A composition formed by the combination of

a) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; with

b) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons.

12. The composition according to claim 11 , wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran is a second aqueous solution or dispersion.

13. The composition according to claim 12 , wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to a total weight of the solution or dispersion.

14. The composition according to claim 12 , wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.

15. The composition according to claim 11 , wherein the aminodextran and the oxidized dextran are finely divided powders.

16. The composition according to claim 11 , wherein the equivalent weight per aldehyde group of the oxidized dextran is about 90 to about 1500 Daltons.

17. A product comprising the dried hydrogel of claim 7 .

18. The product according to claim 17 , wherein said dried hydrogel is a film.

19. The product according to claim 17 , wherein said dried hydrogel is finely divided particles.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2011
From: E.I. DU PONT DE NEMOURS AND COMPANY
To: ACTAMAX SURGICAL MATERIALS, LLC
Reel/Frame 026056/0539 →